Sort by
Refine Your Search
-
Listed
-
Program
-
Field
-
Compatible Growth (CCG) programme and the Strategic Hydrogen Integration for Effective Low-Carbon Development (SHIELD) in Ukraine project and is fixed-term until 31 March 2026. CCG is a £95m UK ODA-funded
-
, operations research, computer science, mathematical finance, or a related field, the successful candidate will demonstrate the ability to develop independent research ideas and contribute to advancing our
-
the impact of RdDM on seed development, particularly how the maternal somatic cells impact the developing seed. We work with a variety of plant systems and use genetic, molecular, and computational approaches
-
with an international reputation for excellence. The Department has a substantial research programme, with major funding from Medical Research Council (MRC), Wellcome Trust and National Institute
-
Leedham (colorectal cancer biology), Dan Woodcock (cancer genomics), Helen Byrne (mathematical modelling), and Jens Rittscher (computational pathology and imaging AI), offering a unique opportunity to work
-
the UKRI through the Frontier Guarantee Programme to Dr Jani R Bolla. The work is to be conducted in his lab in the Department Biology, University of Oxford, South Parks Road, Oxford, OX1 3RB
-
Hospital site in Oxford – a friendly, welcoming place of work with an international reputation for excellence. The Department has a substantial research programme, with major funding from Medical Research
-
using in vivo models. The role will also include supporting the general program of research within the pre-clinical team. You will work in Containment level 2 and 3 facilities to assist with murine
-
With the human population estimated to reach 9.8 billion people by 2050, the looming nitrogen (N) crisis, stemming from the intensive use of fertilisers in agriculture, requires urgent global action. Massive synthesis and application of fertiliser N has a large energy cost, causes CO2 release...
-
Institute for Molecular and Computational Medicine (IMCM). You will test GSK assets and targets in established models of podocyte and mesangial cell pathology relevant to glomerular diseases. You will